Boehringer Ingelheim Licenses Autoimmune Drug from Kyowa Kirin

Autoimmune diseases represent a significant and growing global health issue, affecting approximately 10% of the population and imposing a considerable burden on both patients and healthcare systems.

 Despite progress in therapeutic innovations, there remains a substantial need for more durable and effective treatment options.

To deliver highly customized new medications, Boehringer Ingelheim, a distinguished leader in the research and development of autoimmune diseases, is creating innovative strategies that target the fundamental causes of these disorders.

Also Read: Dr Reddy's Faces Delay in Semaglutide Launch in Canada

“Our commitment to delivering life changing therapies for patients with autoimmune diseases is unwavering.  We are pleased to add a potential first in class program to our growing pipeline,” said Carine Boustany, US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim.

“This agreement constitutes an important step toward delivering breakthrough treatments for patients.”  

Takeyoshi Yamashita, Ph.D., executive vice president and chief medical officer of Kyowa Kirin, commented, “This compound, discovered through Kyowa Kirin’s deep expertise in innovative technology and disease biology, holds tremendous potential.

Leveraging Boehringer Ingelheim’s renowned expertise in inflammatory diseases, we are confident that this innovation will be developed efficiently and delivered to the patients who need it most.”